海特生物：拟境外发行股份（H股）并在香港联合交易所上市

Core Viewpoint - The company, Haitai Biotech (300683.SZ), announced plans to initiate the preparatory work for issuing H-shares and listing on the Hong Kong Stock Exchange by October 22, 2025, aiming to enhance its global strategy and accelerate overseas business development [1] Group 1: Strategic Intent - The company aims to deepen its global strategy and enhance its international brand image through the issuance of H-shares [1] - The move is intended to create a diversified capital operation platform [1] Group 2: Implementation Details - The company plans to discuss specific implementation steps with intermediary institutions, although details are not yet finalized [1] - The issuance and listing of H-shares will require approval from the board of directors, shareholders, and relevant government and regulatory agencies, indicating significant uncertainty in the process [1]